Unknown

Dataset Information

0

An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.


ABSTRACT:

Purpose

A recent phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki disease (KD) patients reported promising results. Here, we aimed to characterize the immunological impact of IL-1 blockade in this unique study population.

Methods

Patients' and control sera and supernatants of cells (whole blood, neutrophils, coronary artery endothelial cells) stimulated with recombinant IL-1β were analyzed for single or multiple marker (n = 22) expression by ELISA or multiplexed bead array assay. Data were analyzed using unsupervised hierarchical clustering, multiple correlation, and multi-comparison statistics and were compared to retrospective analyses of KD transcriptomics.

Results

Inflammation in IVIG-resistant KD (n = 16) is hallmarked by over-expression of innate immune mediators (particularly IL-6 > CXCL10 > S100A12 > IL-1Ra). Those as well as levels of immune or endothelial cell activation markers (sICAM-1, sVCAM-1) declined most significantly in course of anakinra treatment. Prior as well as following IL-1R blockade, over-expression of leucine-rich-α2-glycoprotein 1 (LRG1) associated best with remnant inflammatory activity and the necessity to escalate anakinra dosage and separated inflammatory KD patients from sJIA-MAS (n = 13) and MIS-C (n = 4). Protein as well as retrospective gene expression analyses indicated tight association of LRG1 with IL-1β signaling and neutrophilia, while particularly neutrophil stimulation with recombinant IL-1β resulted in concentration-dependent LRG1 release.

Conclusion

Our study identifies LRG1 as known trigger of endothelial activation and cardiac re-modeling to associate with IL-1β signaling in KD. Besides a potential patho-mechanistic implication of these findings, our data suggest blood leukocyte and neutrophil counts to best predict response to IL-1Ra treatment in IVIG-resistant KD.

SUBMITTER: Kessel C 

PROVIDER: S-EPMC9537216 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.

Kessel Christoph C   Koné-Paut Isabelle I   Tellier Stéphanie S   Belot Alexandre A   Masjosthusmann Katja K   Wittkowski Helmut H   Fuehner Sabrina S   Rossi-Semerano Linda L   Dusser Perrine P   Marie Isabelle I   Boukhedouni Nadja N   Agostini Helène H   Piedvache Céline C   Foell Dirk D  

Journal of clinical immunology 20220614 6


<h4>Purpose</h4>A recent phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki disease (KD) patients reported promising results. Here, we aimed to characterize the immunological impact of IL-1 blockade in this unique study population.<h4>Methods</h4>Patients' and control sera and supernatants of cells (whole blood, neutrophils, coronary artery endothelial cells) stimulated with recombinant IL-1β were analyzed for single or  ...[more]

Similar Datasets

| S-EPMC7137487 | biostudies-literature
| S-EPMC9946247 | biostudies-literature
| S-EPMC8428710 | biostudies-literature
| S-EPMC5623762 | biostudies-literature
| S-EPMC9955912 | biostudies-literature
| S-EPMC10289387 | biostudies-literature
| S-EPMC3776841 | biostudies-literature
| S-EPMC7263588 | biostudies-literature
| S-EPMC10045934 | biostudies-literature
| S-EPMC8341842 | biostudies-literature